Survey on Acceptance of Passive Technology Monitoring for Early Detection of Cognitive Impairment.
Survey on Acceptance of Passive Technology Monitoring for Early Detection of Cognitive Impairment.
复制标题
对早期发现认知障碍的被动技术监测的接受度调查。
DOI：
10.1159/000512207
复制
发表时间：
2021
影响因子：
--
通讯作者：
Smith,KaraM
中科院分区：
文献类型：
--
作者：
Josephy-Hernandez,Sylvia;Norise,Catherine;Han,Jee-Young;Smith,KaraM
数字生物标志物可以作为早期检测认知变化的工具。重要的是要了解公众对专注于监测认知的技术的看法，以更好地指导这些工具的设计，并适当地告知患者相关的风险和益处。卫生保健系统也可能发挥作用的临床，法律的，和财政的影响，这样的technology.ObjectiveEvaluate舆论对使用被动技术监测cognition.MethodsThis是一个一次性的，基于互联网的调查进行英语和Spanish.ResultsWithin英语调查分布在美国（n = 173），58.1%的受访者非常有可能同意通过智能手机应用程序被动监测认知。38%的技术经验丰富的人可能同意监测，而技术经验较少的人只有20%（p = 0.003）。62%的非卫生保健专业人员可能同意监测，而卫生保健工作者的这一比例为45%（p = 0.012）。对隐私有显著关注（p <0.01）。我们通过logistic回归（n = 43，总n = 216）比较了哥斯达黎加西班牙语回答的调查，调整了年龄，教育水平，医疗保健专业，拥有智能手机，技术经验和认知下降的感知。哥斯达黎加/西班牙语受访者选择同意这种技术的可能性高7倍（p <0.01）。来自美国的讲英语的受访者5倍更有可能关注的影响，对健康保险（p = 0.001）和人寿保险（p = 0.01）。ConclusionsUnderstanding公众的看法和道德影响应该指导设计的数字生物标志物的认知。隐私和参与者参与的医疗保健系统是需要考虑的两个主要因素。研究人员有责任传达认知监测的伦理和法律的含义。
IntroductionDigital biomarkers may act as a tool for early detection of changes in cognition. It is important to understand public perception of technologies focused on monitoring cognition to better guide the design of these tools and inform patients appropriately about the associated risks and benefits. Health care systems may also play a role in the clinical, legal, and financial implications of such technologies.ObjectiveTo evaluate public opinion on the use of passive technology for monitoring cognition.MethodsThis was a one-time, Internet-based survey conducted in English and Spanish.ResultsWithin the English survey distributed in the USA (n= 173), 58.1% of respondents would be highly likely to agree to passive monitoring of cognition via a smartphone application. Thirty-eight percent of those with a higher degree of experience with technology were likely to agree to monitoring versus 20% of those with less experience with technology (p= 0.003). Sixty-two percent of non-health-care professionals were likely to agree to monitoring versus 45% of health-care workers (p= 0.012). There were significant concerns regarding privacy (p< 0.01). We compared the surveys answered in Spanish in Costa Rica via logistic regression (n= 43, total n= 216), adjusting for age, education level, health-care profession, owning a smartphone, experience with technology, and perception of cognitive decline. Costa Rican/Spanish-speaking respondents were 7 times more likely to select a high probability of agreeing to such a technology (p< 0.01). English-speaking respondents from the USA were 5 times more likely to be concerned about the impact on health insurance (p= 0.001) and life insurance (p= 0.01).ConclusionsUnderstanding public perception and ethical implications should guide the design of digital biomarkers for cognition. Privacy and the health-care system in which the participants take part are 2 major factors to be considered. It is the responsibility of researchers to convey the ethical and legal implications of cognition monitoring.